Arthrogen GOLDIC is the Next Generation Regeneration Cell Therapy. Blood stimulated to upregulate growth factors to stimulate site specific Stem Cell production. Daryl- orchestrates sales of Human and Veterinary applications. His other duties include sales management, business development, executive leadership, product development, and P&L responsibility.Daryl trains and manages doctors & distributors in the USA. Daryl has submitted documents to the FDA for human & veterinary approval of GOLDIC. He oversees all company-related growth activities and is the critical link between product development and application with the execution of the go-to-market strategies.Daryl increases the productivity and effectiveness of the global commercial organization by reducing friction in the sales process; develops& executes manufacturing vision and plan of the business strategy to maximize shareholder value. He has spoken from the podium at the National meeting presenting the GOLDIC technology. He developed marketing brochures, flyers, studies, designed the booth for trade shows, He identifies current and new capital projects to expand capacity, improves operating efficiency, increases reliability, produces products with enhanced performance specifications and margins, and reduces costs. Additionally, he analyzes and recommends the current and prospective capital programs to improve productivity and enhances production capabilities.

Arthrogen GOLDIC is the Next Generation Regeneration Cell Therapy. Arthrogen GOLDIC is the Next Generation Regeneration Cell Therapy. Blood stimulated to upregulate growth factors to stimulate site specific Stem Cell production.Daryl- orchestrates global sales of Human and Veterinary applications. His other duties include business development, product application, P&L responsibility, secures Investor funding from Germany, Sweden, USA and Trump Mara-largo Florida. Daryl trains and manages doctors & distributors in Europe & USA. Daryl has submitted documents to FDA for human & veterinary approval of GOLDIC. He oversees all company related growth activities and is the critical link between the product development and application with execution of the go-to-market strategies. Daryl increases the productivity and effectiveness of the global commercial organization by reducing friction in the sales process; develops& executes manufacturing vision and plan of the business strategy to maximize shareholder value. He has spoken from podium at National meeting presenting the GOLDIC technology. He developed marketing materials comprising brochures, flyers, studies, design booth for trade shows, He identifies current and new capital projects to expand capacity, improves operating efficiency, increases reliability, produces products with enhanced performance specifications and margins, and reduces costs. Additionally, he analyzes and recommends current and prospective capital program to improve productivity and enhances production capabilities. Achievements►Implemented USA LLC and established a six-member PhD Board of Directors for the Germany company.►Presented the Science of GOLDIC from the podium at a global PhD regenerative medicine meeting.

At Regenhu, Daryl developed, recommended and implemented strategic business plans for market expansion for both new product & program development and existing product & program growth. He identified emerging trends and corresponding markets segments and developed and implemented corresponding market entrance strategies. He also located high impact potential business deals by contacting both existing and potential members and partners to discover and explore new opportunities. Daryl built, managed and maintained strategic relationships as well as business channels and networks resulting in robust sales pipelines and mission focused strategic opportunities. In addition, he designed and supervised sales & marketing operating budgets and guides preparation of marketing activity reports and presents to executive management.

Artimplant AB, a medical technology company, engages in the development, production, and marketing of degradable implants that regenerate body functions following disease and injury to locomotor organ tissue. The company produces implants for the treatment of osteoarthritis and the reinforcement of weakened soft tissue. It offers CMC Spacer for the treatment of thumb base joint osteoarthritis; STT Spacer for the treatment of osteoarthritis in STT joint in the wrist; MTP Spacer for osteoarthritis in the big toe joint; and CMC Arthro for the treatment of osteoarthritis in the thumb base joint.

C.a.R.e.S. Cartilage Regeneration System - Arthro Kinetics Plc, through its subsidiaries, engages in the development, manufacture, and sale of orthopedic products for patients and physicians in Asia-Pacific, North and Latin America, and Europe. Its products include CaReS, a Matrix based cartilage implant for the surgical treatment of damage to the knee joint; endoscopic spine surgery instruments and consumables for spinal surgery; and Allografts, a bone processing service to produce allograft material. Arthro Kinetics Plc was formerly known as ARS Arthro AG. The company was founded in 1999 and is headquartered in Esslingen, Germany.While completing the C.a.R.e.S. Knee Cartilage Regeneration System USA FDA Clinical Trials at Cleveland Clinic, I began hiring a nationwide distributor sales force to market Endoscopic Minimally Invasive Spine Surgery Discectomy, Foramenolpasty and (RF) Radio Frequency Ablation of Annulus Bulge. My sales team directed its efforts toward Neurosurgeons, Orthopedic Spine Surgeons and Neuro-Radiologist.